TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-64 years~* Surgery: Laparoscopic Hysterectomy surgery~* ASA status: I and II~* Fluent in English~Exclusion Criteria:~* History of allergy to local anesthetics~* History of chronic opioid use~* Pregnant patients~* BMI greater than 30~Drop-out criteria:~* Patient or surgeon request~* Complications related to the procedure

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): sterile normal saline as placebo
- Drug .5% Ropivacaine (Type: ACTIVE_COMPARATOR): Instillation of 20 cc of 0.5% ropivacaine
- 20 cc of 0.25% ropivacaine (Type: ACTIVE_COMPARATOR): Instillation of 20 cc of 0.25% ropivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subjects with type 2 diabetes diagnosed during the past 2 years,~* above 18 years of age,~* drug naive, or have been on metformin less than 3 months~Exclusion Criteria:~* subjects with type 1 diabetes or GAD positive subjects or subjects with long standing diabetes (\>2 years) or subjects who are not drug naive or have been on metformin more than 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Triple Therapy (Type: EXPERIMENTAL): initiation a combination of metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) at the time diabetes is diagnosed
- conventional therapy (Type: ACTIVE_COMPARATOR): sequential addition of metformin, glyburide and basal insulin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* May not have been treated with GLM prior to study enrollment~* Must be able to provide retrospective data concerning extra-articular manifestations and episodes with a recall period of at least 12 months prior to anti-TNF use~* Must have definite AS according to the modified New York criteria in the Netherlands~* Must be candidate for treatment with anti-TNF agent according to the Assessment of SpondyloArthritis International Society (ASAS) consensus~* Must be able to adhere to dose and visit schedules~Exclusion Criteria:~* Any exclusion criteria stated in the Summary of Product Characteristics for golimumab~* Use of any investigational biological or chemical agents within 30 days or 2 half-lives (whichever is longest) of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLM 50 mg (Type: EXPERIMENTAL): GLM given subcutaneously at a dose of 50 mg once monthly for up to 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men and women, age 40-75 yrs, without any disease and need of medication.~* Born, raised and currently living at low altitude (\<800m).~* Written informed consent.~* Kyrgyz ethnicity~Exclusion Criteria:~* Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure.~* Any condition that may interfere with protocol compliance including current heavy smoking (\>20 cigarettes per day or \>20 pack-years with active smoking during the last 10 years), regular use of alcohol.~* Allergy to acetazolamide and other sulfonamides.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- ACETAZOLAMIDE oral capsule (Type: ACTIVE_COMPARATOR): Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
- PLACEBO oral capsule (Type: PLACEBO_COMPARATOR): Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Active choroidal neovascularization (CNV) due to AMD.~2. Prior treatment with at least 4 injections of anti-VEGF agents in the past 6 months and persistent intraretinal and/or subretinal fluid on SD-OCT at each visit during this period.~3. Baseline CST ≥ 270 µm on SD-OCT automated retinal thickness map.~4. Injection of the same anti-VEGF agent at each of the two visits immediately preceding study enrollment.~5. Time interval of 5 weeks (± 1 week) between visits for at least two visits immediately preceding study enrollment.~6. Subjects of either gender aged ≥ 45 years.~7. Provide written informed consent~8. Ability to comply with study and follow-up procedures and return for study visits.~Exclusion Criteria:~1. History of uveitis.~2. Presence of intraocular inflammation, significant epiretinal membrane (causing distortion of macular anatomy per investigator discretion), significant vitreomacular traction (per investigator discretion), macular hole, or vitreous hemorrhage.~3. Any ophthalmic surgery within previous 6 months, including cataract extraction.~4. Any history of vitrectomy or glaucoma surgery (e.g., trabeculectomy, tube shunt).~5. Current prescription eye drop usage (e.g., glaucoma drops, corticosteroid drops, etc.).~6. Any contraindication for topical use of a beta-blocker (e.g., bradycardia, decompensated heart failure, chronic obstructive pulmonary disease, reactive airway disease, asthma, etc.).~7. Any history of sulfonamide allergy.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dorzolamide-timolol (Type: ACTIVE_COMPARATOR): Topical dorzolamide-timolol twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
- Artificial tears (Type: PLACEBO_COMPARATOR): Topical artificial tears twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with confirmed symptomatic PE or DVT who have been treated for 6 or 12 months with VKA or rivaroxaban~Exclusion Criteria:~* Legal lower age limitations (country specific)~* Indication for VKA other than DVT and/or PE~* Patients in whom anticoagulant treatment for their index PE or DVT should be continued~* Childbearing potential without proper contraceptive measures, pregnancy or breast feeding. Proper contraceptive measures are defined as a method of contraception with a failure rate \< 1 % during the course of the study (including the observational period). These methods of contraception according to the note for guidance on non-clinical safety studies for the conduct of human trials for pharmaceuticals (CPMP \[Committee for Proprietary Medicinal Products\]/ICH \[International Conference on Harmonization\]/286/95, modification) include consistent and correct use of hormone containing implants and injectables, combined oral contraceptives, hormone containing intrauterine devices, surgical sterilization, sexual abstinence and vasectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Xarelto, BAY59-7939) (Type: EXPERIMENTAL): Participants were to receive rivaroxaban 20 mg oral tablet once daily
- Placebo (Type: PLACEBO_COMPARATOR): Participants were to receive matching placebo oral tablet once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients aged 18 years or older who are fluent in written and spoken English.~* A primary diagnosis of MDD based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM- IV-TR), single or recurrent episode, without psychotic features.~* A HAM-D17 total score ≥20 at the screening and baseline (study day -1) visits and no more than a 4-point improvement from screening to baseline.~Exclusion Criteria:~* Significant risk of suicide based on clinical judgment.~* Current (within 12 months before baseline) psychoactive substance abuse or dependence (including alcohol), manic episode, posttraumatic stress disorder, obsessive compulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder.~* Current generalized anxiety disorder, panic disorder, or social anxiety disorder.~* History or current evidence of gastrointestinal disease known to interfere with the absorption or excretion of drugs or a history of surgery known to interfere with the absorption or excretion of drugs.~* Any unstable hepatic, renal, pulmonary, cardiovascular, ophthalmologic, neurologic, or other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- desvenlafaxine succinate sustained-release 50 mg/day (Type: EXPERIMENTAL): None
- desvenlafaxine succinate sustained-release 100 mg/day (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical history consistent with NCFBE (cough, chronic sputum production and/or recurrent respiratory infections)~2. Are current sputum producers with a history of chronic expectoration and able to provide a sputum sample during Screening~3. Have at least 2 documented pulmonary exacerbations in the past 12 months before Screening~Exclusion Criteria:~1. Have a primary diagnosis of chronic obstructive pulmonary disease (COPD) or asthma~2. Have bronchiectasis due to cystic fibrosis (CF), hypogammaglobulinemia, common variable immunodeficiency, or alpha1-antitrypsin deficiency~3. Are current smokers~4. Are currently being treated for a nontuberculous mycobacterial lung infection, allergic bronchopulmonary aspergillosis, or tuberculosis~5. Have any acute infections, (including respiratory infections)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Brensocatib 10 mg (Type: EXPERIMENTAL): Participants received brensocatib 10 mg once daily (QD) before breakfast, for 24 weeks.
- Brensocatib 25 mg (Type: EXPERIMENTAL): Participants received brensocatib 25 mg QD before breakfast, for 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received the matching placebo QD before breakfast, for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-Has acne vulgaris on the face, including the nose, with 20 to 100 total lesions (noninflammatory and/or inflammatory).~Exclusion Criteria:~* Has uncontrolled systemic disease(s)~* Has severe cystic acne, acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne)~* Has used topical dapsone within 1 month prior to the screening~* Has used oral dapsone within 2 months prior to screening.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- PK Cohort: ACZONE 7.5% (Type: EXPERIMENTAL): Participants applied ACZONE 7.5 % gel topically, once-daily to the entire face, neck, upper chest, upper back and shoulders starting from Day 1 under maximal use conditions (2 grams per day) for Day 8 consecutive days, followed by a thin layer to their face and acne-affected areas on the upper chest, upper back, and shoulders for next 11 weeks.
- Non-PK Cohort: ACZONE 7.5% (Type: EXPERIMENTAL): Participants applied ACZONE 7.5% gel topically, once-daily in a thin layer to their face and acne-affected areas on upper chest, upper back, and shoulders for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telephone Administered Psychotherapy for the Treatment of Depression for Veterans in Rural Areas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a DSM-IV diagnosis of Major Depressive Disorder as assessed using the MINI~* Has a telephone~* Able to speak and read English~* At least 18 years of age~* Able to give informed consent~* Must be registered at a VA community-based, outpatient clinic (CBOC) at VA Eureka or VA Ukiah or VA Santa Rosa, or VA Manteno, or VA Elgin, or VA La Salle~Exclusion Criteria:~* Has a hearing, voice or visual impairment that would prevent participation in T-CBT~* Meets criteria for dementia~* Is diagnosed with Psychotic Disorder, Bipolar Disorder, substance abuse with clinical consensus, or current severe PTSD.~* Is currently receiving psychotherapy or planning to receive psychotherapy during the 20-week treatment phase of the study~* Has a history of suicide attempts or is at high risk for suicide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 - Telephone CBT (Type: EXPERIMENTAL): Telephone cognitive behavioral therapy
- Arm 2 - Treatment as Usual (Type: NO_INTERVENTION): Treatment as usual control.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects were male or non-pregnant females, 18 years of age or older, in generally good health. Females who were post-menopausal, surgically sterile or using a medically acceptable form of birth control with a negative urine pregnancy test at the Baseline visit.~* Subjects provided written and verbal informed consent.~* Subjects presented to the clinic with at least 4 but no more than 12 visible, discrete nonhyperkeratotic, nonhypertrophic actinic keratosis lesions within a 25 cm2 Treatment Area on the face and/or anterior scalp.~* Subjects were willing and able to comply with study instructions and return to the clinic for required visits.~Exclusion Criteria:~* Subjects who were lactating, or planning to become pregnant during the study.~* Subjects had hyperkeratotic, hypertrophic or large mat-like AKs within the 25 cm2 Treatment Area.~* Subjects who had the need or were planning to be exposed to artificial tanning devices or excessive sunlight during the trial.~* Subjects who were immunosuppressed (e.g., HIV, systemic malignancy, graft vs. host disease, etc.).~* Subjects who experienced an unsuccessful outcome from previous imiquimod therapy.~* Subjects with known hypersensitivity or previous allergic reaction to any of the active or inactive components of the study drugs.~* Within 2 months: Facial and/or Anterior Scalp: laser resurfacing, photodynamic therapy, chemical peels, dermabrasion, topical application of 5-FU, imiquimod, diclofenac sodium or other treatments for AK or photodamage.~* Subjects who used the following systemic, oral or topical therapies for the periods specified prior to entry into the study:~Within 2 days: Topicals of any kind to the selected Treatment Area. Within 2 weeks: Facial topical medications: corticosteroids, alpha- hydroxyacids (e.g., glycolic acid, lactic acid, etc. greater than 5%), beta-hydroxyacid (salicylic acid greater than 2%), urea - greater than 5% or prescription retinoids (e.g., tazarotene, adapalene, tretinoin) to the face and/or anterior scalp.~Within 2 weeks: Cryotherapy to lesions adjacent to or within the 25 cm2 Treatment Area.~Within 4 weeks: Systemic steroid therapy: chemotherapeutic agents, psoralens, immunotherapy, or retinoids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Generic Imiquimod (Type: ACTIVE_COMPARATOR): imiquimod cream, 5%
- Aldara™ (Type: ACTIVE_COMPARATOR): Aldara™ (imiquimod) cream, 5%
- Vehicle cream (Type: PLACEBO_COMPARATOR): Vehicle cream (Actavis)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Male~* 18-65 years old~* BMI between 18-40~* Not participated in clinical trial and received either an investigational or marketed drug within two months prior to the study~* Not donated blood in previous two months~Exclusion Criteria:~* Women~* History of local or systemic infection disease with fever or requiring antibiotic within 4 weeks of drug administration~* Corrected QT interval above normal~* Laboratory test results that is more than 1.5 fold outside normal range and/or is judged to be clinically significant~* Current addition to alcohol or substances of abuse~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation~* Use of system course of corticosteroids or other medication known to cause insulin resistance in previous 6 weeks~* Hyperthyroidism,hypothyroidism, hypertension (even if controlled with medications), heart disease (including CAD and CHF), cardiac arrhythmias, diabetes, unstable vasomotor system, or use of monoamine oxidase (MAO) inhibitors~* Diagnosis of bladder outlet obstruction or use of any medication to treat overactive bladder (e.g. Tolterodine, Solifenacin, Propiverine, Oxybutynin, and Fesoterodine)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- beta3-adrenergic receptor agonist (Type: EXPERIMENTAL): single dose. Each subject was randomized to receive placebo at one visit and then the beta3-adrenergic receptor agonist on another study day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete